EMPA-REG Data Will Boost Jardiance's Role In Combination Therapy, Lilly Says
Executive Summary
Large outcomes trial showing a cardiovascular benefit with empagliflozin could shift the treatment landscape to earlier use of the SGLT2 inhibitor in combination therapy rather than replacing treatment with metformin and other agents, Lilly Diabetes President Conterno predicts.
You may also be interested in...
FDA Warning On SGLT-2 Drugs Raises Specter Of Labeling Change
FAERS reports identify cases of diabetic ketoacidosis, ordinarily rare in type 2 diabetes, which were not associated with high blood sugar levels.
Paxlovid Prescribing Complicated By Dosing Adjustment For Renal Impairment, Drug-Drug Interactions
In the EUA for Pfizer’s COVID-19 oral antiviral treatment, US FDA required a reduced dose for some renally impaired patients that is ‘incongruent with how Paxlovid is packaged,’ meaning that pharmacists have to manually make changes to each blister pack. Prescribers will have to navigate an extensive list of contraindicated medicines due to CYP3A effects.
Merck/Ridgeback’s COVID-19 Drug Molnupiravir Met EUA Bar, But More Data Needed For Full Approval – US FDA
Reviewers believed it was worth making the oral antiviral available for second-line use under the relatively low bar for emergency authorization despite the drug’s significant potential risks, ‘modest benefit’ and ‘unexplained difference’ in efficacy results from the interim and full analysis populations in the pivotal trial.